The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib enzalutamide vs placebo enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS Perioperative apalutamide ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3) 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT) 6️⃣ 4500 — RADICAL (A031801) Radium-223 cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up Enfortumab vedotin pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 Perioperative intravesical rBCG chemo-IO strategy in MIBC (primary analysis) 🔟 4510 — KEYNOTE-905 HRQoL with perioperative enfortumab vedotin pembrolizumab in cisplatin-ineligible MIBC Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

Looking forward to the @ASCO @PallOncCoP Meeting! Excited for discussions on anticipatory grief, supportive oncology, patient advocacy, & treatment toxicities w an incredible panel of speakers and advocates 🗓 May 30 | ⏰ 4:30–6 PM CT | 📍 Room E253cd @realbowtiedoc